Northwestern Medicine scientists have discovered that an FDA-approved compound promotes neuroprotective effects in experimental models of Parkinson’s disease. The compound, N-acetyl-L-leucine (NALL), simultaneously targets multiple molecular…
Continue Reading
News Source: medicalxpress.com
Leave a Reply